The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
The neurobiological basis of cognitive impairment in Parkinson's disease
Open accessAbstract
The recent formalization of clinical criteria for Parkinson's disease with dementia (PDD) codifies many studies on this topic, including those assessing biological correlates. These studies show that the emergence of PDD occurs on the background of severe dopamine deficits with, the main pathological drivers of cognitive decline being a synergistic effect between alpha‐synuclein and Alzheimer's disease pathology. The presence of these pathologies correlates with a marked loss of limbic and cortically projecting dopamine, noradrenaline, serotonin, and acetylcholine neurons, although the exact timing of these relationships remains to be determined. Genetic factors, such as triplications in the α‐synuclein gene, lead to a clear increased risk of PDD, whereas others, such as parkin mutations, are associated with a reduced risk of PDD. The very recent formalization of clinical criteria for PD with mild cognitive impairment (PD‐MCI) allows only speculation on its biological and genetic bases. Critical assessment of animal models shows that chronic low‐dose MPTP treatment in primates recapitulates PD‐MCI over time, enhancing the current biological concept of PD‐MCI as having enhanced dopamine deficiency in frontostriatal pathways as well as involvement of other neurotransmitter systems. Data from other animal models support multiple transmitter involvement in cognitive impairment in PD. Whereas dopamine dysfunction has been highlighted because of its obvious role in PD, the role of the other neurotransmitter systems, neurodegenerative pathologies, and genetic factors in PD‐MCI remains to be fully elucidated. © 2014 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Self-citationClinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders · doi:10.1002/mds.24893 · Cited by 2,609
Self-citationThe Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,246
Self-citationMulticenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
The hippocampal-VTA loop: controlling the entry of information into long-term memory
Lisman, J. E., & Grace, A. A. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.002 · Cited by 1,983
Genome-wide association study reveals genetic risk underlying Parkinson's disease
Simón-Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., et al. (2009) · Nature Genetics · doi:10.1038/ng.487 · Cited by 1,751
Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.485 · Cited by 1,324
Dopamine and the regulation of cognition and attention
Nieoullon, A. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00011-4 · Cited by 1,131
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“Hippocampal sclerosis (HS), the loss of neurons and presence of gliosis in the CA1 region of the hippocampus and subiculum,(29) may be found in 10% of AD cases.(30) In PDD, one study found HS in only 1 of 17 cases,(20) a second study found no correlation between HS and PDD,(12) and a third study found 4.”
BackgroundCausal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease
Ibáñez, P., Bonnet, A.-M., Débarges, B., Lohmann, E., Tison, F., Agid, Y., Dürr, A., Brice, A., & Pollak, P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17104-3 · Cited by 1,044
The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,010
Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria
Dickson, D. W., Braak, H., Duda, J. E., Duyckaerts, C., Gasser, T., Halliday, G. M., Hardy, J., Leverenz, J. B., Del Tredici, K., Wszolek, Z. K., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70238-8 · Cited by 972
Self-citationEvolution of cognitive dysfunction in an incident Parkinson's disease cohort
Williams-Gray, C. H., Foltynie, T., Brayne, C. E. G., Robbins, T. W., & Barker, R. A. (2007) · Brain · doi:10.1093/brain/awm111 · Cited by 934
Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70212-x · Cited by 881
FRONTO-STRIATAL COGNITIVE DEFICITS AT DIFFERENT STAGES OF PARKINSON'S DISEASE
OWEN, A. M., JAMES, M., LEIGH, P. N., SUMMERS, B. A., MARSDEN, C. D., QUINN, N. P., LANGE, K. W., & ROBBINS, T. W. (1992) · Brain · doi:10.1093/brain/115.6.1727 · Cited by 868
Scatton, B., Javoy-Agid, F., Rouquier, L., Dubois, B., & Agid, Y. (1983) · Brain Research · doi:10.1016/0006-8993(83)90993-9 · Cited by 726
the Arizona Parkinson’s Disease Consortium, Beach, T. G., Adler, C. H., Lue, L., Sue, L. I., Bachalakuri, J., Henry-Watson, J., Sasse, J., Boyer, S., Shirohi, S., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0538-8 · Cited by 698
Self-citationAlpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease
Hurtig, H. I., Trojanowski, J. Q., Galvin, J., Ewbank, D., Schmidt, M. L., Lee, V. M. Y., Clark, C. M., Glosser, G., Stern, M. B., Gollomp, S. M., et al. (2000) · Neurology · doi:10.1212/wnl.54.10.1916 · Cited by 601
Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?
Compta, Y., Parkkinen, L., O'Sullivan, S. S., Vandrovcova, J., Holton, J. L., Collins, C., Lashley, T., Kallis, C., Williams, D. R., de Silva, R., et al. (2011) · Brain · doi:10.1093/brain/awr031 · Cited by 583
The cholinergic system and Parkinson disease
Bohnen, N. I., & Albin, R. L. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.12.048 · Cited by 566
Anatomy of the Serotonergic Systema
TÖRK, I. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb16870.x · Cited by 557
The Neuropathologic Basis of Different Clinical Subgroups of Parkinson's Disease
Paulus, W., & Jellinger, K. (1991) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199111000-00006 · Cited by 554
Neuropathologic substrates of Parkinson disease dementia
Irwin, D. J., White, M. T., Toledo, J. B., Xie, S. X., Robinson, J. L., Van Deerlin, V., Lee, V. M. ‐., Leverenz, J. B., Montine, T. J., Duda, J. E., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23659 · Cited by 518
Self-citationParkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse
Itier, J.-M. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg239 · Cited by 508
Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry
Owen, A. M. (2004) · The Neuroscientist · doi:10.1177/1073858404266776 · Cited by 496
Widespread origin of the primate mesofrontal dopamine system
Williams, S. (1998) · Cerebral Cortex · doi:10.1093/cercor/8.4.321 · Cited by 467
Advances in the genetics of Parkinson disease
Trinh, J., & Farrer, M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.132 · Cited by 466
Rolinski, M., Fox, C., Maidment, I., & McShane, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006504.pub2 · Cited by 418
The progression of pathology in longitudinally followed patients with Parkinson’s disease
Halliday, G., Hely, M., Reid, W., & Morris, J. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0344-8 · Cited by 414
Self-citationRelationships between age and late progression of Parkinson's disease: a clinico-pathological study
Kempster, P. A., O'Sullivan, S. S., Holton, J. L., Revesz, T., & Lees, A. J. (2010) · Brain · doi:10.1093/brain/awq059 · Cited by 410
Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease
Halliday, G. M., Li, Y. W., Blumbergs, P. C., Joh, T. H., Cotton, R. G. H., Howe, P. R. C., Blessing, W. W., & Geffen, L. B. (1990) · Annals of Neurology · doi:10.1002/ana.410270405 · Cited by 408
Self-citationParkinson Disease Neuropathology: Later-Developing Dementia and Loss of the Levodopa Response
Apaydin, H., Ahlskog, J. E., Parisi, J. E., Boeve, B. F., & Dickson, D. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.1.102 · Cited by 399
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication
Fuchs, J., Nilsson, C., Kachergus, J., Munz, M., Larsson, E.-M., Schüle, B., Langston, J. W., Middleton, F. A., Ross, O. A., Hulihan, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000254458.17630.c5 · Cited by 397
The pedunculopontine nucleus in Parkinson's disease
Zweig, R. M., Jankel, W. R., Hedreen, J. C., Mayeux, R., & Price, D. L. (1989) · Annals of Neurology · doi:10.1002/ana.410260106 · Cited by 386
Dementia in Parkinson disease: Functional imaging of cholinergic and dopaminergic pathways
Hilker, R., Thomas, A. V., Klein, J. C., Weisenbach, S., Kalbe, E., Burghaus, L., Jacobs, A. H., Herholz, K., & Heiss, W. D. (2005) · Neurology · doi:10.1212/01.wnl.0000191154.78131.f6 · Cited by 384
APOE ϵ4 Increases Risk for Dementia in Pure Synucleinopathies
Tsuang, D., Leverenz, J. B., Lopez, O. L., Hamilton, R. L., Bennett, D. A., Schneider, J. A., Buchman, A. S., Larson, E. B., Crane, P. K., Kaye, J. A., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.600 · Cited by 378
Self-citationPreferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
Kish, S. J., Tong, J., Hornykiewicz, O., Rajput, A., Chang, L.-J., Guttman, M., & Furukawa, Y. (2007) · Brain · doi:10.1093/brain/awm239 · Cited by 375
Dissecting the diversity of midbrain dopamine neurons
Roeper, J. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.03.003 · Cited by 373
Bohnen, N. I., Kaufer, D. I., Hendrickson, R., Ivanco, L. S., Lopresti, B. J., Constantine, G. M., Mathis, C. A., Davis, J. G., Moore, R. Y., & DeKosky, S. T. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0971-0 · Cited by 364
Mattila, P. M., Rinne, J. O., Helenius, H., Dickson, D. W., Röyttä, M., & Mattila, P. M. (2000) · Acta Neuropathologica · doi:10.1007/s004019900168 · Cited by 361
Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo
Klein, J. C., Eggers, C., Kalbe, E., Weisenbach, S., Hohmann, C., Vollmar, S., Baudrexel, S., Diederich, N. J., Heiss, W. D., & Hilker, R. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d55f61 · Cited by 356
The genetics of Parkinson's disease: Progress and therapeutic implications
Singleton, A. B., Farrer, M. J., & Bonifati, V. (2013) · Movement Disorders · doi:10.1002/mds.25249 · Cited by 354
Greffard, S., Verny, M., Bonnet, A.-M., Beinis, J.-Y., Gallinari, C., Meaume, S., Piette, F., Hauw, J.-J., & Duyckaerts, C. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.584 · Cited by 354
Neuropathology of dementia in Parkinson's disease: A prospective, community‐based study
Aarsland, D., Perry, R., Brown, A., Larsen, J. P., & Ballard, C. (2005) · Annals of Neurology · doi:10.1002/ana.20635 · Cited by 348
Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra
Rinne, J. O., Mlic, J. R., Paljärvi, L., & Rinne, U. K. (1989) · Annals of Neurology · doi:10.1002/ana.410260107 · Cited by 331
Dopamine: a key regulator to adapt action, emotion, motivation and cognition
Nieoullon, A., & Coquerel, A. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200312002-00002 · Cited by 315
Prognosis of Mild Cognitive Impairment in Early Parkinson Disease: The Norwegian ParkWest Study
Pedersen, K. F., Larsen, J. P., Tysnes, O.-B., & Alves, G. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2110 · Cited by 315
Lewis, S. J. G., Slabosz, A., Robbins, T. W., Barker, R. A., & Owen, A. M. (2005) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2004.10.001 · Cited by 309
The progression of pathology in Parkinson's disease
Halliday, G. M., & McCann, H. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05118.x · Cited by 299
Self-citationCortical Lewy body pathology in the diagnosis of dementia
Harding, A. J., & Halliday, G. M. (2001) · Acta Neuropathologica · doi:10.1007/s004010100390 · Cited by 297
Self-citationImpact of coexistent Alzheimer pathology on the natural history of Parkinson's disease
Jellinger, K. A., Seppi, K., Wenning, G. K., & Poewe, W. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200027 · Cited by 287
Dementia in idiopathic Parkinson's disease: A neuropathological study of 32 cases
Gaspar, P., & Gray, F. (1984) · Acta Neuropathologica · doi:10.1007/bf00695605 · Cited by 275
Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies
Schneider, J. A., Arvanitakis, Z., Yu, L., Boyle, P. A., Leurgans, S. E., & Bennett, D. A. (2012) · Brain · doi:10.1093/brain/aws234 · Cited by 273
Self-citationCognitive impairments associated with early Parkinson's disease
Levin, B. E., Llabre, M. M., & Weiner, W. J. (1989) · Neurology · doi:10.1212/wnl.39.4.557 · Cited by 273
Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease
Goris, A., Williams‐Gray, C. H., Clark, G. R., Foltynie, T., Lewis, S. J. G., Brown, J., Ban, M., Spillantini, M. G., Compston, A., Burn, D. J., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21192 · Cited by 270
GBA-associated PD presents with nonmotor characteristics
Brockmann, K., Srulijes, K., Hauser, A.-K., Schulte, C., Csoti, I., Gasser, T., & Berg, D. (2011) · Neurology · doi:10.1212/wnl.0b013e318225ab77 · Cited by 268
Neuropathology of non-motor features of Parkinson disease
Dickson, D. W., Fujishiro, H., Orr, C., DelleDonne, A., Josephs, K. A., Frigerio, R., Burnett, M., Parisi, J. E., Klos, K. J., & Ahlskog, J. E. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70769-2 · Cited by 266
Cognitive performance of GBA mutation carriers with early-onset PD: The CORE-PD study
Alcalay, R. N., Caccappolo, E., Mejia-Santana, H., Tang, M.-X., Rosado, L., Orbe Reilly, M., Ruiz, D., Ross, B., Verbitsky, M., Kisselev, S., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318253d54b · Cited by 262
Cognitive impairment and dementia in Parkinson's disease
Pagonabarraga, J., & Kulisevsky, J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.029 · Cited by 257
Ehrt, U., Broich, K., Larsen, J. P., Ballard, C., & Aarsland, D. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.186239 · Cited by 254
Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys
Schneider, J. S., & Kovelowski, C. J. (1990) · Brain Research · doi:10.1016/0006-8993(90)90069-n · Cited by 246
Self-citationThe interplay of cholinergic function, attention, and falls in Parkinson's disease
Yarnall, A., Rochester, L., & Burn, D. J. (2011) · Movement Disorders · doi:10.1002/mds.23932 · Cited by 237
Del Tredici, K., & Braak, H. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301817 · Cited by 236
Cognitive impairment in Parkinson's disease
Verbaan, D., Marinus, J., Visser, M., van Rooden, S. M., Stiggelbout, A. M., Middelkoop, H. A. M., & van Hilten, J. J. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.112367 · Cited by 235
Age‐specific progression of nigrostriatal dysfunction in Parkinson's disease
de la Fuente‐Fernández, R., Schulzer, M., Kuramoto, L., Cragg, J., Ramachandiran, N., Au, W. L., Mak, E., McKenzie, J., McCormick, S., Sossi, V., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22284 · Cited by 222
Calabresi, P., Castrioto, A., Di Filippo, M., & Picconi, B. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70118-2 · Cited by 210
Parkinson Disease With Dementia: Comparing Patients With and Without Alzheimer Pathology
Sabbagh, M. N., Adler, C. H., Lahti, T. J., Connor, D. J., Vedders, L., Peterson, L. K., Caviness, J. N., Shill, H. A., Sue, L. I., Ziabreva, I., et al. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31819c5ef4 · Cited by 209
Self-citationAβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases
Pletnikova, O., West, N., Lee, M. K., Rudow, G. L., Skolasky, R. L., Dawson, T. M., Marsh, L., & Troncoso, J. C. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.10.006 · Cited by 209
Hereditary form of parkinsonism—dementia
Muenter, M. D., Forno, L. S., Hornykiewicz, O., Kish, S. J., Maraganore, D. M., Caselli, R. J., Okazaki, H., Howard, F. M., Snow, B. J., & Calne, D. B. (1998) · Annals of Neurology · doi:10.1002/ana.410430612 · Cited by 201
Lewy body cortical involvement may not always predict dementia in Parkinson's disease
Colosimo, C. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.7.852 · Cited by 200
Evolution of mild cognitive impairment in Parkinson disease
Broeders, M., de Bie, R. M. A., Velseboer, D. C., Speelman, J. D., Muslimovic, D., & Schmand, B. (2013) · Neurology · doi:10.1212/wnl.0b013e31829c5c86 · Cited by 200
Waxman, E. A., & Giasson, B. I. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0297-11.2011 · Cited by 194
Impulse control disorders in Parkinson's disease: recent advances
Voon, V., Mehta, A. R., & Hallett, M. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283489687 · Cited by 193
Heterogeneity of Cholinergic Denervation in Parkinson's Disease without Dementia
Bohnen, N. I., Müller, M. L. T. M., Kotagal, V., Koeppe, R. A., Kilbourn, M. R., Gilman, S., Albin, R. L., & Frey, K. A. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.60 · Cited by 185
Modeling Parkinson's Disease in Primates: The MPTP Model
Porras, G., Li, Q., & Bezard, E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009308 · Cited by 181
Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study)
Reid, W. G. J., Hely, M. A., Morris, J. G. L., Loy, C., & Halliday, G. M. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.232678 · Cited by 180
Self-citationKulisevsky, J. (2000) · Drugs & Aging · doi:10.2165/00002512-200016050-00006 · Cited by 177
Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease
Narayanan, N. S., Rodnitzky, R. L., & Uc, E. Y. (2013) · Reviews in the Neurosciences · doi:10.1515/revneuro-2013-0004 · Cited by 176
Neurodegeneration and Motor Dysfunction in a Conditional Model of Parkinson's Disease
Nuber, S., Petrasch-Parwez, E., Winner, B., Winkler, J., von Hörsten, S., Schmidt, T., Boy, J., Kuhn, M., Nguyen, H. P., Teismann, P., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3040-07.2008 · Cited by 176
Rinne, J. O., Ma, S. Y., Lee, M. S., Collan, Y., & Röyttä, M. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.01.006 · Cited by 175
Age-dependent cognitive decline and amygdala pathology in α-synuclein transgenic mice
Freichel, C., Neumann, M., Ballard, T., Müller, V., Woolley, M., Ozmen, L., Borroni, E., Kretzschmar, H. A., Haass, C., Spooren, W., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.013 · Cited by 174
DJ‐1 mutations and parkinsonism‐dementia‐amyotrophic lateral sclerosis complex
Annesi, G., Savettieri, G., Pugliese, P., D'Amelio, M., Tarantino, P., Ragonese, P., La Bella, V., Piccoli, T., Civitelli, D., Annesi, F., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20666 · Cited by 173
Dopamine overdose hypothesis: Evidence and clinical implications
Vaillancourt, D. E., Schonfeld, D., Kwak, Y., Bohnen, N. I., & Seidler, R. (2013) · Movement Disorders · doi:10.1002/mds.25687 · Cited by 171
Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease
Zabetian, C. P., Hutter, C. M., Factor, S. A., Nutt, J. G., Higgins, D. S., Griffith, A., Roberts, J. W., Leis, B. C., Kay, D. M., Yearout, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21157 · Cited by 165
Attentional control in Parkinson's disease is dependent on COMT val158met genotype
Williams-Gray, C. H., Hampshire, A., Barker, R. A., & Owen, A. M. (2008) · Brain · doi:10.1093/brain/awm313 · Cited by 165
Ito, K., Nagano‐Saito, A., Kato, T., Arahata, Y., Nakamura, A., Kawasumi, Y., Hatano, K., Abe, Y., Yamada, T., Kachi, T., et al. (2002) · Brain · doi:10.1093/brain/awf134 · Cited by 164
Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease
Milber, J. M., Noorigian, J. V., Morley, J. F., Petrovitch, H., White, L., Ross, G. W., & Duda, J. E. (2012) · Neurology · doi:10.1212/wnl.0b013e318278fe32 · Cited by 163
The locus ceruleus and dementia in Parkinson's disease
Zweig, R. M., Cardillo, J. E., Cohen, M., Giere, S., & Hedreen, J. C. (1993) · Neurology · doi:10.1212/wnl.43.5.986 · Cited by 161
Schneider, J. S., Yuwiler, A., & Markham, C. H. (1987) · Brain Research · doi:10.1016/0006-8993(87)90691-3 · Cited by 160
Self-citationGenetic influences on cognitive decline in Parkinson's disease
Morley, J. F., Xie, S. X., Hurtig, H. I., Stern, M. B., Colcher, A., Horn, S. S., Dahodwala, N. A., Duda, J. E., Weintraub, D. A., Chen‐Plotkin, A. S., et al. (2012) · Movement Disorders · doi:10.1002/mds.24946 · Cited by 158
The many faces of alpha‐synuclein mutations
Kasten, M., & Klein, C. (2013) · Movement Disorders · doi:10.1002/mds.25499 · Cited by 157
Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease
Williams‐Gray, C. H., Goris, A., Saiki, M., Foltynie, T., Compston, D. A. S., Sawcer, S. J., & Barker, R. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0119-8 · Cited by 157
Positron Emission Tomography of Striatal Serotonin Transporters in Parkinson Disease
Kerényi, L., Ricaurte, G. A., Schretlen, D. J., McCann, U. D., Varga, J., Mathews, W. B., Ravert, H. T., Dannals, R. F., Hilton, J., Wong, D. F., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1223 · Cited by 154
Huot, P., Johnston, T. H., Darr, T., Hazrati, L., Visanji, N. P., Pires, D., Brotchie, J. M., & Fox, S. H. (2010) · Movement Disorders · doi:10.1002/mds.23083 · Cited by 153
Chahine, L. M., Qiang, J., Ashbridge, E., Minger, J., Yearout, D., Horn, S., Colcher, A., Hurtig, H. I., Lee, V. M.-Y., Van Deerlin, V. M., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1274 · Cited by 150
Self-citationProgression of monoaminergic dysfunction in parkinson's disease: a longitudinal 18f-dopa pet study
Pavese, N., Rivero-Bosch, M., Lewis, S. J., Whone, A. L., & Brooks, D. J. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.03.012 · Cited by 145
Marsh, L., Biglan, K., Gerstenhaber, M., & Williams, J. R. (2008) · Movement Disorders · doi:10.1002/mds.22307 · Cited by 144
Specific A10 Dopaminergic Nuclei in the Midbrain Degenerate in Parkinson's Disease
McRitchie, D. A., Cartwright, H., & Halliday, G. M. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6418 · Cited by 138
Self-citationClinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism
Li, Y., Tomiyama, H., Sato, K., Hatano, Y., Yoshino, H., Atsumi, M., Kitaguchi, M., Sasaki, S., Kawaguchi, S., Miyajima, H., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000164009.36740.4e · Cited by 138
Perry, E. K., McKeith, I. G., THOMPSON, P., MARSHALL, E., Kerwin, J. M., Jabeen, S., Edwardson, J. A., Ince, P. G., Blessed, G., Irving, D., et al. (1991) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1991.tb00217.x · Cited by 138
Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease
Mattila, P. M., Röyttä, M., Torikka, H., Dickson, D. W., & Rinne, J. O. (1998) · Acta Neuropathologica · doi:10.1007/s004010050843 · Cited by 133
Neuropathologic Basis of Age-Associated Brain Atrophy
Erten‐Lyons, D., Dodge, H. H., Woltjer, R. L., Silbert, L. C., Howieson, D. B., Kramer, P., & Kaye, J. A. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1957 · Cited by 132
Mattila, P. M., Röyttä, M., Lönnberg, P., Marjamäki, P., Helenius, H. Y. M., & Rinne, J. O. (2001) · Acta Neuropathologica · doi:10.1007/s004010100372 · Cited by 131
Treatment of Psychosis and Dementia in Parkinson’s Disease
Goldman, J. G., & Holden, S. K. (2014) · Current Treatment Options in Neurology · doi:10.1007/s11940-013-0281-2 · Cited by 128
Goldman, J. G., Holden, S. K., Bernard, B. A., Ouyang, B., Goetz, C. G., & Stebbins, G. T. (2013) · Movement Disorders · doi:10.1002/mds.25655 · Cited by 127
Non‐motor behavioural impairments in parkin‐deficient mice
Zhu, X., Maskri, L., Herold, C., Bader, V., Stichel, C. C., Güntürkün, O., & Lübbert, H. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05812.x · Cited by 120
Poletti, M., & Bonuccelli, U. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312470130 · Cited by 113
A large study reveals no association between APOE and Parkinson's disease
Federoff, M., Jimenez‐Rolando, B., Nalls, M. A., & Singleton, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.02.002 · Cited by 110
Cognitive deficits in a mouse model of pre‐manifest Parkinson’s disease
Magen, I., Fleming, S. M., Zhu, C., Garcia, E. C., Cardiff, K. M., Dinh, D., Rosa, K. D. L., Sánchez, M. Á., Torres, E. R. S., Masliah, E., et al. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08012.x · Cited by 110
Attention and executive function deficits in chronic low‐dose MPTP‐treated non‐human primates
Decamp, E., & Schneider, J. S. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03586.x · Cited by 109
Self-citationGoldwurm, S., Zini, M., Fonzo, A. D., Gaspari, D. D., Siri, C., Simons, E. J., van Doeselaar, M., Tesei, S., Antonini, A., Canesi, M., et al. (2006) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2006.04.001 · Cited by 108
Schneider, J. S., & Pope-Coleman, A. (1995) · Neurodegeneration · doi:10.1016/1055-8330(95)90014-4 · Cited by 106
Self-citationSchneider, J. S., & Roeltgen, D. P. (1993) · Brain Research · doi:10.1016/0006-8993(93)90049-s · Cited by 105
Self-citationSerotonin and dopamine striatal innervation in Parkinson’s disease and Huntington’s chorea
Bédard, C., Wallman, M., Pourcher, E., Gould, P. V., Parent, A., & Parent, M. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.05.012 · Cited by 103
Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration
Amador, C., Ahmed, Z., Zehr, C., & Dickson, D. W. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0183-4 · Cited by 100
Cognitive performance in early Parkinson's disease
Hietanen, M., & Teräväinen, H. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1986.tb03257.x · Cited by 100
Schneider, J. S. (1990) · Brain Research · doi:10.1016/0006-8993(90)90108-n · Cited by 96
Self-citationMagnetic resonance imaging: A biomarker for cognitive impairment in Parkinson's disease?
Duncan, G. W., Firbank, M., O'Brien, J. T., & Burn, D. J. (2013) · Movement Disorders · doi:10.1002/mds.25352 · Cited by 95
Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases
Cheng, A. V., Ferrier, I. N., Morris, C. M., Jabeen, S., Sahgal, A., McKeith, I. G., Edwardson, J. A., Perry, R. H., & Perry, E. K. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90193-b · Cited by 95
Belarbi, S., Hecham, N., Lesage, S., Kediha, M. I., Smail, N., Benhassine, T., Ysmail-Dahlouk, F., Lohman, E., Benhabyles, B., Hamadouche, T., et al. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.09.003 · Cited by 94
Heterogeneous neuropathological findings in Parkinson’s disease with mild cognitive impairment
Adler, C. H., Caviness, J. N., Sabbagh, M. N., Shill, H. A., Connor, D. J., Sue, L. I., Evidente, V. G. H., Driver‐Dunckley, E. D., & Beach, T. G. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0744-4 · Cited by 90
Self-citationWaeber, C., & Palacios, J. M. (1989) · Neuroscience · doi:10.1016/0306-4522(89)90082-1 · Cited by 86
Thalamic noradrenaline in Parkinson's disease: Deficits suggest role in motor and non‐motor symptoms
Pifl, C., Kish, S. J., & Hornykiewicz, O. (2012) · Movement Disorders · doi:10.1002/mds.25109 · Cited by 86
Strecker, K., Wegner, F., Hesse, S., Becker, G., Patt, M., Meyer, P., Lobsien, D., Schwarz, J., & Sabri, O. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5666-5 · Cited by 85
Ghebremedhin, E., Rosenberger, A., Rüb, U., Vukšić, M., Berhe, T., Bickeböller, H., de Vos, R. A. I., Thal, D. R., & Deller, T. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181d88e63 · Cited by 84
Li, X., Redus, L., Chen, C., Martinez, P. A., Strong, R., Li, S., & O’Connor, J. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071341 · Cited by 67
Neuropathologic features associated with Alzheimer disease diagnosis: Age matters
Middleton, L. E., Grinberg, L. T., Miller, B. L., Kawas, C. H., & Yaffe, K. S. (2011) · Neurology · doi:10.1212/wnl.0b013e318236f0cf · Cited by 67
Lower cognitive performance in healthy G2019S LRRK2 mutation carriers
Thaler, A., Mirelman, A., Gurevich, T., Simon, E. S., Orr‐Urtreger, A., Marder, K. S., Bressman, S., Giladi, N., Bressman, S., Saunders-Pullman, R. J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182684646 · Cited by 63
Small‐vessel disease in patients with Parkinson's disease: A clinicopathological study
Schwartz, R. S., Halliday, G. M., Cordato, D. J., & Kril, J. J. (2012) · Movement Disorders · doi:10.1002/mds.25112 · Cited by 62
Self-citationIsaias, I. U., Marotta, G., Pezzoli, G., Sabri, O., Schwarz, J., Crenna, P., Claßen, J., & Cavallari, P. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-88 · Cited by 62
α-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells
Wilkaniec, A., Strosznajder, J. B., & Adamczyk, A. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.08.004 · Cited by 59
Alcalay, R. N., Mejia‐Santana, H., Tang, M. X., Rakitin, B. C., Rosado, L., Ross, B., Verbitsky, M., Kisselev, S., Louis, E. D., Comella, C. L., et al. (2010) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390903521018 · Cited by 58
Monoaminergic activities in Lewy Body dementia: Relation to hallucinosis and extrapyramidal features
Perry, E. K., Marshall, E., Thompson, P., McKeith, I. G., Collerton, D., FAIRBAIRN, A. F., Ferrier, I. N., Irving, D., & Perry, R. H. (1993) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260919 · Cited by 57
Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology
Monsell, S. E., Mock, C., Roe, C. M., Ghoshal, N., Morris, J. C., Cairns, N. J., & Kukull, W. A. (2013) · Neurology · doi:10.1212/wnl.0b013e318295d7a1 · Cited by 57
Cognitive dysfunction in Tunisian LRRK2 associated Parkinson’s disease
Sassi, S. B., Nabli, F., Hentati, E., Nahdi, H., Trabelsi, M., Ayed, H. B., Amouri, R., Duda, J. E., Farrer, M. J., & Hentati, F. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.10.009 · Cited by 50
Somme, J. H., Gómez‐Esteban, J. C., Molano, A., Tijero, B., Lezcano, E., & Zarranz, J. J. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.07.047 · Cited by 50
Task persistence and learning ability in normal and chronic low dose MPTP-treated monkeys
Roeltgen, D. P., & Schneider, J. S. (1994) · Behavioural Brain Research · doi:10.1016/0166-4328(94)90138-4 · Cited by 48
Self-citationChoi, S.-A., Evidente, V. G. H., Caviness, J. N., Shill, H. A., Sabbagh, M. N., Connor, D. J., Hentz, J. G., Adler, C. H., & Beach, T. G. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0620-2 · Cited by 48
Self-citationNeuropathology in Parkinson’s disease with mild cognitive impairment
Jellinger, K. A. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0755-1 · Cited by 45
Locus coeruleus neuron density and parkinsonism in older adults without Parkinson's disease
Buchman, A. S., Nag, S., Shulman, J. M., Lim, A. S. P., VanderHorst, V., Leurgans, S. E., Schneider, J. A., & Bennett, D. A. (2012) · Movement Disorders · doi:10.1002/mds.25142 · Cited by 43
Self-citationMood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease
Shanker, V., Groves, M., Heiman, G. A., Palmese, C. A., Saunders-Pullman, R. J., Ozelius, L. J., Raymond, D., & Bressman, S. (2011) · Movement Disorders · doi:10.1002/mds.23746 · Cited by 42
Levodopa improves motor deficits but can further disrupt cognition in a macaque parkinson model
Schneider, J. S., Pioli, E. Y., Jianzhong, Y., Li, Q., & Bézard, E. (2012) · Movement Disorders · doi:10.1002/mds.25258 · Cited by 40
Self-citationRay, N. J., & Strafella, A. P. (2012) · Movement Disorders · doi:10.1002/mds.25173 · Cited by 35
Substantia Nigra, Ventral Tegmental Area, and Retrorubral Fields
Halliday, G. M., Reyes, S., & Double, K. L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-374236-0.10013-6 · Cited by 35
Self-citationHindle, J. V. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-0994-0 · Cited by 33
Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra
Reyes, S., Cottam, V., Kirik, D., Double, K. L., & Halliday, G. M. (2013) · Movement Disorders · doi:10.1002/mds.25493 · Cited by 27
Self-citationCaccappolo, E., Alcalay, R. N., Mejia‐Santana, H., Tang, M., Rakitin, B. C., Rosado, L., Louis, E. D., Comella, C. L., Colcher, A., Jennings, D. L., et al. (2010) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617710001190 · Cited by 25
Amyloid angiopathy in idiopathic Parkinson's disease. Immunohistochemical and ultrastructural study.
Bertrand, E., Lewandowska, E., Stępień, T., Szpak, G. M., Pasennik, E., & Modzelewska, J. (2008) · PubMed · Cited by 25
Rinne, J. O., Rummukainen, J., ̈rvi, L. P., et al. (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802030-00078 · Cited by 24
Hall, H., Jewett, M. A. S., Landeck, N., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064844 · Cited by 23
Age-associated prevalence and risk factors of Lewy body pathology in a general population
Jellinger, K. A. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0751-9 · Cited by 20
Pathological substrate of dementia in Parkinson's disease—Its relation to DLB and DLBD
Jellinger, K. A. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.09.001 · Cited by 19
Genetic Rat Models of Parkinson's Disease
Welchko, R. M., Lévêque, X., & Dunbar, G. L. (2012) · Parkinson s Disease · doi:10.1155/2012/128356 · Cited by 16
Mental and Behavioral Dysfunction in Movement Disorders
Groves, M. (2004) · Journal of Neuropsychiatry · doi:10.1176/jnp.16.4.539 · Cited by 13
Prevalence of hippocampal sclerosis in a clinicopathologically characterized cohort
Malek‐Ahmadi, M. H., Kahlon, V., Adler, C. H., Obradov, A., Thind, K., Shill, H. A., Sue, L. I., Caviness, J. N., Jacobson, S. A., & Sabbagh, M. N. (2013) · Clinical and Experimental Medical Sciences · doi:10.12988/cems.2013.13026 · Cited by 9
Self-citationThe Role of Dopamine Replacement on the Behavioural Phenotype of Parkinson’s Disease
Alobaidi, H., & Pall, H. (2013) · Behavioural Neurology · doi:10.1155/2013/902016 · Cited by 9
Induction and Reversal of Cognitive Deficits in a Primate Model of Parkinson's Disease
Schneider, J. S. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-326-2_13 · Cited by 2
Self-citation
Cited by
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Cognitive decline in Parkinson disease
Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.27 · Cited by 1,027
Parkinson’s disease dementia: a neural networks perspective
Gratwicke, J., Jahanshahi, M., & Foltynie, T. (2015) · Brain · doi:10.1093/brain/awv104 · Cited by 435
Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?
Jellinger, K. A., & Korczyn, A. D. (2018) · BMC Medicine · doi:10.1186/s12916-018-1016-8 · Cited by 385
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
Metadata
- Authors
- Halliday, G. M., Leverenz, J. B., Schneider, J. S., & Adler, C. H.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2014-04-15
- Volume
- 29
- Issue
- 5
- Pages
- 634-650
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1672024307
- Cited by
- 366
- References
- 160
- FWCI
- 18.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.